featured
Second-Line XELIRI Regimen vs Irinotecan Monotherapy in Advanced Biliary Tract Cancer Patients Progressed on Gemcitabine and Cisplatin
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
British Journal of Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
A Randomised Phase II Study of Second-Line XELIRI Regimen Versus Irinotecan Monotherapy in Advanced Biliary Tract Cancer Patients Progressed on Gemcitabine and Cisplatin
Br. J. Cancer 2018 Jun 29;[EPub Ahead of Print], Y Zheng, X Tu, P Zhao, W Jiang, L Liu, Z Tong, H Zhang, C Yan, W Fang, W WangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.